Method and composition for treatment of inflammatory bowel disease

Abstract

A composition in unit dosage form for the inhibition, prevention or treatment of inflammatory bowel disease comprising an effective amount of a compound having the formula: and a pharmaceutically acceptable carrier therefor. Also disclosed is a method for the inhibition, prevention or treatment of inflammatory bowel disease comprising administering to a human or non-human mammal in need thereof an effective amount of a compound having the formula:

I claim:  
     
         1 . A composition in unit dosage form for the inhibition, prevention or treatment of inflammatory bowel disease comprising an effective amount of a compound and a pharmaceutically acceptable carrier therefor, the compound having the formula:  
       
         
           
           
               
               
           
         
       
       wherein: 
 Z is CH or N;  
 R is H or acyl;  
 R 1 , R 2 , R 3  and R 5  may be the same or different and represent H, alkyl or hydrocarbyl arylalkyl having up to 14 carbon atoms; and  
 R 4  is H, alkyl having 1-6 carbon atoms or OR.  
 
     
     
         2 . A composition according to  claim 1  wherein said compound has the formula:  
       
         
           
           
               
               
           
         
       
     
     
         3 . A composition according to  claim 2  wherein said compound is the (R)-enantiomer thereof.  
     
     
         4 . A composition according to  claim 2  wherein said compound is the (S)-enantiomer thereof.  
     
     
         5 . A composition according to  claim 1  wherein said compound has the formula:  
       
         
           
           
               
               
           
         
       
     
     
         6 . A composition according to  claim 5  wherein said compound is the (R)-enantiomer thereof.  
     
     
         7 . A composition according to  claim 5  wherein said compound is the (S)-enantiomer thereof.  
     
     
         8 . A composition according to  claim 1  wherein said effective amount is sufficient to provide a dosage when administered to a human or non-human mammal in need thereof of from about 2 to about 500 mg/kg.  
     
     
         9 . A method for the inhibition, prevention or treatment of inflammatory bowel disease comprising administering to a human or non-human mammal in need thereof an effective amount of a compound having the formula [A] or [B] of  claim 1 .  
     
     
         10 . The method of  claim 9  wherein said compound is topically administered to the colon of said mammal.  
     
     
         11 . The method of  claim 10  wherein said compound is administered by rectal enema or by means of an orally ingested unit dosage.  
     
     
         12 . The method of  claim 11  wherein said compound is administered in an amount in the range of from about 2 to about 500 mg/kg.  
     
     
         13 . A composition in unit dosage form adapted for topical administration to the colon of a human or non-human mammal for the inhibition, prevention or treatment of inflammatory bowel disease comprising an effective amount of desferrioxamine B, a homolog or analog thereof and a pharmaceutically acceptable carrier therefor, said desferrioxamine B, homolog or analog thereof having the formula:  
       
         
           
           
               
               
           
         
       
       wherein: 
 each n may be the same or different and is an integer from 1-10;  
 each m may be the same or different and is an integer from 2-6;  
 a and b are integers from 1-6;  
 c is an integer from 0-10;  
 R is a straight or branched chain alkyl having 1-14 carbon atoms or aryl; and  
 R 1  and R 2  are straight or branched chain alkyls having 1-10 carbon atoms.  
 
     
     
         14 . A composition according to  claim 13  comprising desferrioxamine B.  
     
     
         15 . A composition according to  claim 13  wherein said effective amount is sufficient to provide a dosage when administered to a human or non-human mammal in need thereof of from about 2 to about 500 mg/kg.  
     
     
         16 . A method for the inhibition, prevention or treatment of inflammatory bowel disease comprising topically administering to the colon of a human or non-human mammal in need thereof an effective amount of a compound having the formula [C], [D], [E] or [F] of  claim 13 .  
     
     
         17 . The method of  claim 16  wherein-said compound is administered by rectal enema or by means of an orally ingested unit dosage.